Sugi Predict

Sugi Predict / Targets / DPYD

DPYD

Dihydropyrimidine dehydrogenase [NADP(+)] · Q12882 · DPYD on Sugi Atlas →

1,210 patent compounds predicted against DPYD, 643 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Eniluracil Eniluracil (SCHEMBL37817) 1.00 5/20
SCHEMBL170251 SCHEMBL170251 1.00 5/20
SCHEMBL289873 SCHEMBL289873 1.00 5/20
5-Bromouracil 5-Bromouracil (SCHEMBL8224638) 0.76 5/20
Eniluracil Eniluracil (SCHEMBL5392934) 0.73 5/20
SCHEMBL14793573 SCHEMBL14793573 0.66 5/20
SCHEMBL48228 SCHEMBL48228 0.65 5/20
SCHEMBL10696940 SCHEMBL10696940 0.65 5/20
SCHEMBL1228163 SCHEMBL1228163 0.63 5/20
SCHEMBL1916591 SCHEMBL1916591 0.63 5/20
SCHEMBL65892 SCHEMBL65892 0.62 5/20
SCHEMBL190003 SCHEMBL190003 0.62 5/20
SCHEMBL15798473 SCHEMBL15798473 0.62 5/20
SCHEMBL28624115 SCHEMBL28624115 0.62 5/20
SCHEMBL190328 SCHEMBL190328 0.59 5/20
SCHEMBL190329 SCHEMBL190329 0.59 5/20
SCHEMBL13296 SCHEMBL13296 0.59 5/20
SCHEMBL190377 SCHEMBL190377 0.59 5/20
SCHEMBL190378 SCHEMBL190378 0.59 5/20
SCHEMBL933037 SCHEMBL933037 0.59 5/20

Clinical trials — most relevant to DPYD by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment PHASE4RECRUITING
Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy PHASE4COMPLETED
Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients PHASE4UNKNOWN
Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients PHASE4COMPLETED
Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer PHASE3COMPLETED
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer PHASE2/PHASE3RECRUITING
Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer PHASE3COMPLETED
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer PHASE2COMPLETED
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene PHASE2COMPLETED
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer PHASE2COMPLETED
Study of the Impact of DPD Activity on the Efficacy of Capecitabine PHASE2ACTIVE_NOT_RECRUITING
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. PHASE2RECRUITING
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer PHASE2UNKNOWN
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer PHASE2UNKNOWN
Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy PHASE2RECRUITING
Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab PHASE2UNKNOWN
XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer PHASE2UNKNOWN
Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines PHASE1COMPLETED
A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors PHASE1SUSPENDED
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer PHASE1RECRUITING
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. nanCOMPLETED
Improving the Safety of Fluoropyrimidine-based Chemotherapy nanUNKNOWN
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer nanUNKNOWN
The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line nanUNKNOWN
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines nanCOMPLETED
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine nanCOMPLETED
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients nanRECRUITING
Mechanistic Studies of Teriflunomide in RRMS nanCOMPLETED
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer nanCOMPLETED
Chilean Gastric Cancer Task Force (FORCE 1) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DPYD binder may also engage these)

ProteinNameSimilarity
Q5R895 — 1.000 Q5R895 →
Q28943 — 1.000 Q28943 →
Q28007 — 1.000 Q28007 →
Q8CHR6 — 0.999 Q8CHR6 →
Q6NYG8 — 0.997 Q6NYG8 →
O89000 — 0.997 O89000 →
Q2RAK2 — 0.971 Q2RAK2 →
O09171 — 0.970 O09171 →
Q5RDD3 — 0.968 Q5RDD3 →
Q5RFG2 — 0.967 Q5RFG2 →
Q2QXR8 — 0.967 Q2QXR8 →
B8BJ39 — 0.966 B8BJ39 →
Q16134 — 0.965 Q16134 →
O35490 — 0.962 O35490 →
B8BM17 — 0.962 B8BM17 →
P55931 — 0.961 P55931 →
Q5M8Z0 — 0.960 Q5M8Z0 →
Q5XGM3 — 0.960 Q5XGM3 →
BHMT Betaine--homocysteine S-methyltransferase 1 0.960 landscape →
Q6UPE1 — 0.960 Q6UPE1 →
Q2KIG0 — 0.959 Q2KIG0 →
O80526 — 0.959 O80526 →
Q2QZ86 — 0.958 Q2QZ86 →
P11029 — 0.957 P11029 →
P11497 — 0.957 P11497 →
ACACA Acetyl-CoA carboxylase 1 0.956 landscape →
Q5SWU9 — 0.956 Q5SWU9 →
Q3T0V9 — 0.955 Q3T0V9 →
Q5I597 — 0.955 Q5I597 →
Q2QNG7 — 0.955 Q2QNG7 →